^
Association details:
| Biomarker: | ER positive + PIK3CA H1047R |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Orserdu (elacestrant) (Selective estrogen receptor degrader) + OKI-219 (PI3Kα H1047R mutation inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
OKI-219, a PI3KαH1047R-mutant-selective inhibitor demonstrates efficacy as a single agent and drives combination responses with standard of care therapies in pre-clinical PI3KαH1047R mutant breast cancer models.
Published date:
12/02/2023
Excerpt:
Moreover, OKI-219 dosed in combination with the selective estrogen receptor degraders (SERDs) fulvestrant, elacestrant or camizestrant showed significant combination benefit leading to tumor regressions of up to 100% in the ER+ H1047R mutant breast cancer model xxT47D, at doses where no regressions were observed with single agent treatment.
